Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson
Apr 7, 2017
by Dave Williamson
Pharma’s Diabetes War Escalates
Apr 7, 2017
by Dave Williamson
Aeterna Zentaris Casts a Lifeline
Apr 7, 2017
by Dave Williamson
This Biotech’s Well Never Runs Dry
Apr 7, 2017
by Dave Williamson
BioSante Waves the White Flag
Apr 7, 2017
by Dave Williamson
Hedge Fund Guru Loves This Stock
Apr 7, 2017
by Dave Williamson
Is Wall Street Turning on Amarin?
Apr 7, 2017
by Dave Williamson
Why Rigel Is Plunging
Apr 7, 2017
by Dave Williamson
How Far Can Sarepta Run?
Apr 7, 2017
by Dave Williamson
This Big Biotech Has a Big Winner
Apr 7, 2017
by Dave Williamson
Is Cell Therapeutics Roaring Back?
Apr 7, 2017
by Dave Williamson
Why ArQule Was Chopped In Half
Apr 7, 2017
by Dave Williamson
2 Obesity Drugs Near the Finish Line for Launch
Apr 7, 2017
by Dave Williamson
1 Big Pharma That's Not Waving the White Flag
Apr 7, 2017
by Dave Williamson
3 Stocks Shaking Up Health Care
Apr 7, 2017
by Dave Williamson
Can Discovery Labs Keep Winning?
Apr 7, 2017
by Dave Williamson
Can Threshold Turn It Around?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.